Published in Int J Radiat Oncol Biol Phys on July 01, 1986
New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol (2008) 0.98
Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. Exp Ther Med (2011) 0.79
Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide. Br J Cancer (1993) 0.75
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
More on managing metastatic choroidal tumors. Oncology (Williston Park) (1989) 5.12
Expression of the T-box family genes, Tbx1-Tbx5, during early mouse development. Dev Dyn (1996) 3.34
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol (1996) 2.56
Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology (1977) 2.55
Plasmacytoma. Treatment results and conversion to myeloma. Cancer (1992) 2.50
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol (1999) 2.48
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Improved methodology for analyzing local and distant recurrence. J Clin Oncol (1990) 2.21
Carcinoma of the cervix: predictive value of clinical and magnetic resonance (MR) imaging assessment of prognostic factors. Int J Radiat Oncol Biol Phys (1993) 2.13
Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer (1993) 2.07
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res (1993) 1.99
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol (1995) 1.96
Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys (1997) 1.93
Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med (1977) 1.93
Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. Radiology (1975) 1.90
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys (1986) 1.87
Letter: "High-dose" metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials. Br J Radiol (1974) 1.87
Tbx6, a mouse T-Box gene implicated in paraxial mesoderm formation at gastrulation. Dev Biol (1996) 1.86
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol (1997) 1.73
Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg (1994) 1.72
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys (1995) 1.71
Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res (1993) 1.71
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys (1998) 1.71
Experience in charged particle irradiation of tumors of the skull base: 1977-1992. Int J Radiat Oncol Biol Phys (1994) 1.70
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
Uveal melanoma. Growth rate and prognosis. Arch Ophthalmol (1997) 1.67
Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1998) 1.66
Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am (1998) 1.63
A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys (1991) 1.63
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene (1999) 1.62
Transcatheter occlusion of the arterial duct with Cook detachable coils: early experience. Heart (1996) 1.62
Public health oncology: a framework for progress in low- and middle-income countries. Ann Oncol (2012) 1.59
Transport of membrane-bound macromolecules by M cells in follicle-associated epithelium of rabbit Peyer's patch. Cell Tissue Res (1987) 1.59
RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys (1995) 1.57
High-dose-rate versus low-dose-rate intracavitary brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys (1990) 1.56
Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys (1999) 1.50
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol (1992) 1.49
Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol (1990) 1.46
Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res (1994) 1.44
Prognostic factors for patients with Hodgkin disease in first relapse. Cancer (1993) 1.42
Failure of preenucleation radiation to decrease uveal melanoma mortality. Am J Ophthalmol (1988) 1.42
Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl (1978) 1.42
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol (1998) 1.40
NICE guidance does not tally with clinical practice--a district general experience. Rheumatology (Oxford) (2007) 1.39
Vision following helium ion radiotherapy of uveal melanoma: a Northern California Oncology Group study. Int J Radiat Oncol Biol Phys (1988) 1.39
Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Intern Med (1982) 1.38
Radiation therapy for stage I and IIA testicular seminoma. Int J Radiat Oncol Biol Phys (1994) 1.38
Research in medical physics. Int J Radiat Oncol Biol Phys (2001) 1.37
Oxidative injury rapidly activates the heat shock transcription factor but fails to increase levels of heat shock proteins. Cancer Res (1993) 1.36
Evolution of mouse T-box genes by tandem duplication and cluster dispersion. Genetics (1996) 1.35
The clinical pharmacology of antineoplastic agents (first of two parts). N Engl J Med (1975) 1.35
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys (1994) 1.34
A Carboniferous insect gall: insight into early ecologic history of the Holometabola. Proc Natl Acad Sci U S A (1996) 1.34
Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys (1986) 1.32
Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 1.32
The chemotherapy of urologic cancer. Cancer (1975) 1.32
The neurotoxicity of misonidazole: pooling of data from five centres. Br J Radiol (1978) 1.31
Desmoid tumors--treatment and prognosis. Radiology (1977) 1.26
Economic evaluation of interventions to reduce road traffic injuries--a review of the literature with applications to low and middle-income countries. Asia Pac J Public Health (2004) 1.26
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1994) 1.25
Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer (1982) 1.24
Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery (1995) 1.21
A novel technique for measuring human tissue pO2 at the cellular level. Br J Cancer (1986) 1.21
An ultrastructural study of the development of radiation injury in the lung. Radiology (1966) 1.21
National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy (2009) 1.18
Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys (1983) 1.17
Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest (1974) 1.16
Kidney cell proliferation after unilateral nephrectomy as related to age. Cancer Res (1967) 1.16
Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res (1980) 1.16
Malignant fibrous histiocytoma with widespread metastases. Autopsy study. Cancer (1974) 1.15
Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer (1975) 1.15
Thoracic wall involvement by Hodgkin disease and non-Hodgkin lymphoma: CT evaluation. Radiology (1985) 1.14
Malignant tumors of the testis: analysis of treatment results and sites and causes of failure. Cancer (1977) 1.14
The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol (1980) 1.12
Radiation retinopathy. Int J Radiat Oncol Biol Phys (1979) 1.12
Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology (1985) 1.11
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol (2001) 1.11
Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res (1988) 1.11
Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys (1996) 1.11
Cost benefit of emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys (1997) 1.11
Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys (1993) 1.11
Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol (2000) 1.09
Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys (1988) 1.08
Radiation response of artificial pulmonary metastases of the EMT6 tumor. Int J Radiat Oncol Biol Phys (1976) 1.08
Radiobiological characterization of the inactivating events produced in mammalian cells by helium and heavy ions. Int J Radiat Oncol Biol Phys (1977) 1.08
Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res (1994) 1.08
Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 1.07
High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys (1993) 1.07
Stereotaxic irradiation of brain tumors. Cancer (1990) 1.07
The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys (1997) 1.07
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (1979) 1.06